Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients

[1]  F. May,et al.  Prognostic value of cathepsin D in breast cancer , 1999, British Journal of Cancer.

[2]  G. Scambia,et al.  A META-ANALYSIS , 2005 .

[3]  M. Nadji,et al.  Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer. , 1996, Human Pathology.

[4]  M. Emmert-Buck.  Cathepsin D and prognosis in breast cancer: one piece of a larger puzzle? , 1996, Human pathology.

[5]  H. Rochefort,et al.  Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[6]  C. Peters,et al.  Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. , 1995, The EMBO journal.

[7]  J. Isola,et al.  Stromal cell cathepsin D expression and long-term survival in breast cancer. , 1995, British Journal of Cancer.

[8]  T. Maudelonde,et al.  Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. , 1994, Human pathology.

[9]  R. Cardiff.  Cathepsin D and breast cancer: useful? , 1994, Human pathology.

[10]  J. Foekens,et al.  Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Conover,et al.  Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. , 1994, The Journal of biological chemistry.

[12]  S. Fuqua,et al.  Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Potvin,et al.  Prognostic significance of cathepsin‐D expression in node‐positive breast carcinoma: An immunohistochemical study , 1993, International journal of cancer.

[14]  J. Foekens,et al.  Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Robert Gray,et al.  Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis , 1992 .

[16]  G. Striker,et al.  Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years. , 1992, The American journal of pathology.

[17]  Z. Shao,et al.  Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. , 1992, Cancer research.

[18]  H. Rochefort,et al.  MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. , 1991, Experimental cell research.

[19]  P. Pujol,et al.  Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. , 1990, Oncogene.

[20]  K. Ulm,et al.  Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer , 1990 .

[21]  W. McGuire,et al.  Cathepsin D and prognosis in breast cancer. , 1990, The New England journal of medicine.

[22]  J. Cairns,et al.  Prognostic significance of the estrogen‐regulated protein, cathepsin D, in breast cancer. An immunohistochemical study , 1990, Cancer.

[23]  T. Maudelonde,et al.  CATHEPSIN D: AN INDEPENDENT PROGNOSTIC FACTOR FOR METASTASIS OF BREAST CANCER , 1989, The Lancet.

[24]  J. Foekens,et al.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.

[25]  I. Christensen,et al.  Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. , 1989, Cancer research.

[26]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.

[27]  H. Rochefort,et al.  In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. , 1988, Cancer research.

[28]  H. Rochefort,et al.  Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. , 1986, Endocrinology.

[29]  H. Rochefort,et al.  A secreted glycoprotein induced by estrogen in human breast cancer cell lines , 1980, Cell.

[30]  H. Rochefort,et al.  Estradiol induced proteins in the MCF7 human breast cancer cell line. , 1979, Biochemical and biophysical research communications.

[31]  H. D. Brunk,et al.  Statistical inference under order restrictions : the theory and application of isotonic regression , 1973 .

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[33]  H. Rochefort.  The prognostic value of cathepsin D in breast cancer. A long road to the clinic. , 1996, European journal of cancer.

[34]  F. May,et al.  Cathepsin D and breast cancer. , 1996, European journal of cancer.

[35]  H. Rochefort.  Oestrogens, proteases and breast cancer. From cell lines to clinical applications. , 1994, European journal of cancer.

[36]  T. Visakorpi,et al.  Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Ravdin.  Evaluation of cathepsin D as a prognostic factor in breast cancer , 1993, Breast cancer research and treatment.

[38]  T. Dimpfl,et al.  [Prognostic factors in node-negative breast cancer]. , 1993, Gynakologisch-geburtshilfliche Rundschau.

[39]  J. Foekens,et al.  Quality control of cathepsin-D measurement by the EORTC Receptor Study Group. , 1992, European journal of cancer.

[40]  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. , 1980, European Journal of Cancer.

[41]  D.,et al.  Regression Models and Life-Tables , 2022 .